The “valley of death” is a term used in science and medicine to describe the gap between a promising laboratory discovery and an actual treatment that reaches patients. It’s the stage where most potential breakthroughs quietly die, not because the science was wrong, but because funding, business incentives, and regulatory hurdles make it nearly impossible to move forward. In drug development specifically, more than 90% of candidates that enter clinical testing never make it to approval.
Why Most Discoveries Never Become Treatments
The path from a scientific discovery to something a doctor can prescribe is often described as “bench to bedside.” In theory, a researcher identifies a promising compound, tests it in the lab, runs clinical trials, and eventually brings it to market. In practice, developing a single new drug takes 10 to 15 years and costs an average of $1 to $2 billion. The vast majority of attempts fail along the way.
That failure rate is staggering. Nine out of ten drug candidates that reach Phase I clinical trials (the first round of human testing) will ultimately fail during trials or the approval process. And that figure doesn’t even count the compounds that never make it out of the lab. When you include preclinical failures, the true attrition rate is even higher.
The valley of death isn’t a single moment of failure. It’s a sustained stretch, sometimes lasting years, where a project needs enormous resources but generates zero revenue. Researchers have identified two distinct valleys that a medical innovation must cross to survive.
The Two Valleys
The first valley spans the period between an initial discovery and the point where a company licenses the technology. This is where university researchers typically get stuck. A scientist may identify a promising compound, but at that early stage the invention is so undeveloped that licensing it to a pharmaceutical company is extremely difficult. If a university’s technology transfer office can’t find a buyer, the discovery’s commercial potential simply dies. Universities are also reluctant to invest in patents when no obvious licensee has stepped forward, creating a catch-22: without investment the technology can’t mature, but without maturity no one will invest.
The second valley is what most people in the biotech industry picture when they hear the term. It corresponds roughly to the clinical trial period, after a company has acquired or developed a product candidate but before it generates any revenue. This phase produces steeply negative cash flows as a company burns through capital to fund trials. Graphically, it’s often shown as a deep U-shaped dip in a company’s cash position. Many startups simply run out of money here.
The Funding Gap at the Root
A major driver of the valley of death is how research money is distributed. Between 2010 and 2019, 83% of NIH grants, totaling $156 billion, went to basic research. Only 17%, about $31 billion, funded translational research, the work of turning basic discoveries into usable therapies. That means the government heavily funds the initial “what does this do?” science but provides relatively little support for the expensive, messy process of turning those findings into something that works in people.
For small companies trying to bridge the gap, federal Small Business Innovation Research (SBIR) grants are one of the few options. But competition is fierce. In 2024, the overall success rate for NIH SBIR grant applications was just 12%. Phase I applications, the earliest stage, had a 10% success rate. That leaves the vast majority of small biotech firms without the federal funding they need to advance their work.
Regulatory and Manufacturing Hurdles
Money isn’t the only obstacle. Even well-funded projects face a maze of regulatory and technical challenges that can stall progress for years. The National Academies of Sciences has cataloged several categories of barriers that slow or kill promising therapies during development.
- Regulatory complexity: New technologies often don’t fit neatly into existing regulatory frameworks. Different countries have different standards, and global regulatory divergence forces companies to navigate multiple approval systems simultaneously. Regulators themselves may lack technical training in emerging technologies, leading to conservative decision-making based on norms rather than scientific principles.
- Manufacturing inflexibility: Scaling a compound from a lab bench to a production facility introduces entirely new problems, from finding sustainable starting materials to developing efficient purification methods. Many manufacturing operations are rigid and poorly equipped to accommodate novel approaches.
- Business risk aversion: Speed to market is a key driver for pharmaceutical companies. Introducing a new manufacturing technology or unfamiliar process creates potential delays, and most companies aren’t willing to accept that risk. Even when a new approach is scientifically superior, if it might slow the timeline, companies often stick with older methods.
The result is a system where the very innovations designed to improve drug development can themselves become bottlenecks, because the regulatory and business infrastructure hasn’t evolved to accommodate them.
Rare Diseases Fall Hardest
The valley of death hits rare disease communities with particular cruelty. There are roughly 7,000 identified rare diseases affecting an estimated 30 million Americans, about 1 in 10 people. Up to half of those affected are children, and approximately 80% of rare diseases are genetic rather than acquired. Yet 95% of rare diseases have no FDA-approved treatment.
The economics are straightforward and grim: pharmaceutical companies see rare diseases as niche markets with limited profit potential. From 1983 to 2009, the FDA granted 2,112 orphan drug designations but approved only 347 for market, a 16% conversion rate. For many rare disease patients, “no hope” is the default. Some conditions affect so few people that even designing a clinical trial becomes a logistical nightmare. One rare disease family described the challenge of trying to fund a human safety study with just two patients, without support from pharma, biotech, or the NIH.
Efforts to Bridge the Gap
Several strategies have emerged to help discoveries survive the valley of death, though none has solved the problem completely.
The National Center for Advancing Translational Sciences (NCATS), part of the NIH, was created specifically to address bottlenecks in the research pipeline. Its programs include tissue chip technology (miniature models of human organs for testing), drug repurposing efforts that find new uses for existing medications, gene-targeted therapies for rare diseases, and a network that connects clinical trial infrastructure across institutions. NCATS focuses on the science of translation itself, trying to make the entire process faster and more efficient rather than funding individual drugs.
Venture philanthropy has also emerged as a force in translational research. Traditionally, patient advocacy groups and disease foundations provided care, educational resources, and research grants. In recent years, some have adopted a model borrowed from venture capitalism: investing directly in the earliest, riskiest stages of drug development to generate enough preliminary data to attract commercial investors later. These organizations, often driven by families and individuals with a personal stake in finding cures, deliberately step into the gap where government funding ends and private investment hasn’t yet begun.
The logic is simple. Venture philanthropists get in early, where the financial risk is highest, and fund the work that will eventually make a project attractive to capital markets. For diseases that pharmaceutical companies have written off as unprofitable, this model can be the only path forward.